Nevertheless, for patients with advanced disease with castration resistant prostate cancer characterised by a constitutive activation of AR, depending on AR gene point mutations or truncations, there is an urgent need to develop new treatments [34–37]. The gene discussed is AR; the disease is prostate carcinoma.